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Abstract
Background/Objective—Youth with obesity have an altered HDL subspecies profile 
characterized by depletion of large apoE rich HDL particles and an enrichment of small HDL 
particles. The goal of this study was to test the hypothesis that this atherogenic HDL profile would 
be reversed and that HDL function would improve with metabolic surgery.
Methods—Serum samples from adolescent males with severe obesity mean ± SD age of 17.4 
± 1.6 years were studied at baseline and 1 year following vertical sleeve gastrectomy (VSG). HDL 
subspecies and HDL function were evaluated pre and post VSG using paired t-tests. A lean group 
of adolescents was included as a reference group.
Results—After VSG, BMI decreased by 32% and insulin resistance as estimated by HOMA-IR 
decreased by 75% (both p<0.01). Large apoE rich HDL subspecies increased following VSG 
(p<0.01) and approached that of lean adolescents despite participants with considerable residual 
obesity. Additionally, HDL function improved compared to baseline (cholesterol efflux capacity 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding Author/Reprints: Amy S Shah MD MS. Cincinnati Children’s Hospital Medical Center, Division of Endocrinology. 
3333 Burnet Ave ML 7012. Cincinnati OH 45229-3039, USA. amy.shah@cchmc.org. Phone: 513-636-4744. Fax: 513-696-7486. 
Conflict Statement: The authors have no conflicts of interest
Supplementary information is available at International Journal of Obesity’s website
Authors Contributions:
A.S designed the study, analyzed the data and wrote the manuscript, TH recruited the participants and edited the manuscript, HS and 
AH performed the experiments, analyzed the data and edited the manuscript, DE recruited participants from preliminary experiments, 
DH edited the manuscript, JM performed the experiments and edited the manuscript, WSD designed the study and wrote the 
manuscript.
HHS Public Access
Author manuscript
Int J Obes (Lond). Author manuscript; available in PMC 2017 April 26.
Published in final edited form as:
Int J Obes (Lond). 2017 January ; 41(1): 83–89. doi:10.1038/ijo.2016.190.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
increased by 12%, HDL lipid peroxidation potential decreased by 30%, and HDL anti-oxidative 
capacity improved by 25%, all p<0.01).
Conclusions—Metabolic surgery results in a significant improvement in the quantity of large 
HDL subspecies and HDL function. Our data suggest metabolic surgery may improve 
cardiovascular risk in adolescents and young adults.
Key Terms
high density lipoproteins; cholesterol efflux; adolescents; vertical sleeve gastrectomy
Introduction
Pediatric obesity is a major public health concern. More alarming, however, is the rapid rise 
in severe obesity among US adolescents. Severe obesity is defined as an absolute body mass 
index (BMI) >35 or a BMI >120% of the 95th percentile for age and sex, and currently 
affects about 6% of all youth, or 4 million adolescents (1). Emerging data show that youth 
with severe obesity have higher numbers of cardiovascular risk factors, more dyslipidemia, 
and early evidence of cardiac and vascular dysfunction (2) compared to youth with less 
severe obesity. Despite these immediate and serious cardiovascular consequences, treatments 
are limited. Lifestyle intervention, the mainstay of therapy, is often ineffective (3, 4).
As a result, metabolic surgery (also known as bariatric or weight loss surgery) has emerged 
as a potential treatment option in adolescents with severe obesity with studies showing 
effective weight loss (5, 6) and a favorable benefit to risk profile (7). Specifically, weight 
loss surgery improves important metabolic parameters such as insulin resistance (8), as well 
as blood pressure and lipids (5, 6). One important change that occurs following metabolic 
surgery in both adults and youth is a significant and sustained rise in high density lipoprotein 
cholesterol (HDL-C) of 40% or greater (9). However, while a remarkable and reproducible 
finding, it is not clear whether this rise in HDL-C translates into improved cardiovascular 
disease (CVD) risk. Indeed, in adult populations, increases in HDL-C by as much as 70% 
(10, 11) either through pharmacologic intervention or in the setting of genetic mutations 
have not consistently been shown to reduce CVD risk (12).
As a result, attention has shifted from evaluating HDL-C quantity to assessing HDL quality 
as a CVD risk marker. A landmark study by Khera et al. found that HDL function, as 
measured by cholesterol efflux capacity or HDL’s ability to promote efflux of cholesterol 
from macrophages, was independently associated with both subclinical atherosclerosis 
(measured by carotid artery intima-media thickness) and angiographically confirmed 
obstructive coronary heart disease (CAD). Furthermore, in their study cholesterol efflux 
capacity outperformed clinically important measures of total cholesterol, low density 
lipoprotein cholesterol (LDL-C) and HDL-C with respect to decreasing the odds of CAD 
(13). This was later confirmed prospectively by Rohatgi et al. (14). Similarly, other HDL 
functions including HDL anti-oxidative capacity has been shown to be independently 
associated with acute coronary syndrome (15).
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It is often incorrectly assumed that all HDL particles are compositionally homogeneous. 
However, HDL exists as different subspecies each with unique lipid and protein 
compositions (see (16) for a review). Furthermore, not all subspecies are equally 
atheroprotective (17, 18). Thus, it is critically important to evaluate HDL’s subspecies that 
may be integral to vascular function and susceptibility to CVD.
We have previously shown that youth with obesity and those with combined obesity and 
type 2 diabetes exhibit an altered HDL subspecies profile characterized by depletion of large 
apoE rich HDL particles and an enrichment of small HDL particles compared to lean 
adolescents (17). These adolescents also exhibited increased arterial stiffness measured non-
invasively by pulse wave velocity compared to controls (17, 19). Strikingly, a higher number 
of large HDL particles was inversely associated with arterial stiffness but traditional lipid 
markers of total cholesterol, LDL-C and HDL-C were not. From these data, we surmised 
that this altered HDL subspecies profile (reduction in large HDL particles and increased 
small particles) was disadvantageous-tied to either excess adiposity or insulin resistance, or 
perhaps both. In this current study, we asked whether reduction in weight with metabolic 
surgery reverses this unhealthy HDL subspecies profile and improves HDL function. This 
surgical model was chosen for two reasons: 1) significant weight loss and reversal of insulin 
resistance can be achieved with metabolic surgery in a consistent manner (6, 8), and 
importantly 2) studying participants pre- and post-surgery allows each subject to serve as his 
own control thus reducing the number of confounding variables encountered in cross-
sectional studies of individuals with a broad range of BMI values.
Material and Methods
Ten male participants 14–20 years of age undergoing metabolic surgery at Cincinnati 
Children’s Hospital between 2009 and 2011 were offered enrollment in a prospective 
biospecimen repository protocol (Pediatric Obesity Tissue Repository). The decision to 
undergo metabolic surgery and the type of surgery was made collaboratively by the patient, 
caregiver(s), and clinical staff, independent of this research protocol. For this pilot study of 
HDL, only males were selected to eliminate known differences in lipoproteins by sex (20). 
All participants were assessed at baseline and 1 year post-operatively. Height was measured 
to the closest 0.1 cm on a wall mounted stadiometer and weight was measured on an 
electronic scale. Blood pressure was obtained manually using a sphygmomanometer (with 
appropriate cuff size) and auscultation. Major comorbid conditions and laboratory data were 
abstracted from medical records. Written informed consent was obtained from participants ≥ 
18 years old or from the parent or guardian if age <18 years. The study was approved by the 
Institutional Review Board at Cincinnati Children’s Hospital.
Clinical Measurements
Measurements of total cholesterol, HDL-C, and triglycerides (TGs) were performed as 
previously described (17). LDL-C was calculated using the Friedewald equation. Glucose 
was measured using a Hitachi model 704 glucose analyzer (Roche Hitachi, Indianapolis, IN) 
and insulin was measured by radioimmunoassay (RIA) with an anti-insulin serum raised in 
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guinea pigs, 125I-labeled insulin (Linco, St Louis, MO) and a double antibody method to 
separate bound from free tracer.
HDL Functional Assays
Serum stored at −80°C was thawed. HDL was isolated by removing apoB containing 
lipoproteins from serum using polyethylene glycol (PEG, MW 6000, Sigma Aldrich; St. 
Louis, MO). 400 μl PEG (20% in water) was added to 1 ml serum, incubated for 20 min at 
RT, and then centrifuged at 10,000 RPM for 30 min.
A. Cholesterol efflux capacity—HDL most well recognized function is the ability to 
move (efflux) cholesterol from the plasma membrane of macrophages (13). This assay 
measures the net movement (aqueous diffusion, ATP-binding cassette sub-family A1 
(ABCA1) and G member 1 (ABCG1) mediated) of 3H-labeled cholesterol from J774 cells, a 
mouse macrophage cell line (ATCC; Manassas, VA) to an acceptor (apoB depleted plasma) 
where a higher cholesterol efflux capacity is indicative of improved HDL function. J774 
cells were plated in 48-well plates at 200,000 cells per well and radiolabeled with 1 μCi/ml 
of 3H-cholesterol (PerkinElmer; Boston, MA). The next day 150 μl treatments containing 
2.8% v/v of apoB depleted serum were made in basal media (DMEM containing 0.2% BSA) 
with 2 μg/ml ACAT inhibitor and 0.3 mM 8-Br-cAMP were added and incubated for 6 h.
Liquid scintillation counting was used to detect the 3H-cholesterol effluxed to an acceptor 
via scintillation counting. Percent cholesterol efflux is expressed using the following 
formula: 3H count in efflux media/(3H count in efflux media + mean 3H count extracted 
from untreated cells) × 100. All samples were assayed in triplicate. All data was normalized 
to a plasma control and is expressed as cholesterol efflux capacity. Positive controls included 
plasma at 2% v/v, lipid-free apoA-I and HDL (each at 10 μg/ml protein) containing the 
ACAT inhibitor with and without 8-Br-cAMP. Supplement Figure 1 shows reproducibility. 
Interassay coefficient of variation (CV) is 5.3%
HDL lipid peroxidation
HDL lipid peroxidation (or the measured amount of hydrogen peroxide in HDL) was 
measured using an established protocol published by Kelesidis et al (21). This assay utilizes 
Amplex Red in the presence of horseradish peroxidase (HRP) to assess the rate of formation 
of endogenous lipid hydroperoxides in a specific amount of HDL. 50 μl of apoB depleted 
serum with reaction buffer (0.5 M potassium phosphate, pH 7.4, 0.25 M NaCl, 25 mM 
cholic acid, 0.5% Triton X-100) were added to a 96-well black plate. Controls included 
ultracentrifugally isolated HDL (20 μg cholesterol) in 50 μl reaction buffer and a 50 μl 
reaction buffer blank. 50 μl of a solution containing 1–10 U/ml HRP in reaction buffer was 
then added to each well and incubated at 37°C for 1 h. Following incubation, 50 μl of a 
reaction buffer (300 μM Amplex Red and 0.2 U/ml cholesterol esterase) was added. 
Fluorescence was measured at one-minute intervals for 1 h using a Biotek Synergy HT plate 
reader at absorption 530nm and emission 590 nm. Kinetic curve data was analyzed using 
Gen5 2.01 (Biotek; Winooski, VT). A buffer blank control was subtracted from each 
experimental sample. HDL lipid peroxidation was calculated as the rate of oxidation 
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(relative fluorescent units per minute) divided by the cholesterol concentration of each 
sample as measured using a colorimetric kit (Pointe Scientific; Canton, MI).
A lower amount of lipid peroxidation in HDL indicates improved HDL function. 
Reproducibility is shown in ref (21). Interassay CV is 4.0%.
HDL anti-oxidative capacity
HDL anti-oxidative capacity measures HDL’s ability to mitigate oxidation of LDL. Using a 
modified assay from Patel et al.(15), we tested the ability of HDL to react with oxidized 
LDL in the presence of a dihydrorhodamine 123 (DHR, Life Technologies). DHR is a non-
fluorescent substrate that reacts with reactive oxygen species (ROS) in oxidized LDL to 
form the fluorescent compound rhodamine 123. HDL prevents conversion to rhodamine 123 
thus a lower anti-oxidative index indicates improved HDL anti-oxidative capacity. LDL was 
isolated by ultracentrifugation from a single donor (Hoxworth Blood Center, Cincinnati OH) 
and oxidized with 20 nmol CuSO4 (per 1 mg LDL protein). LDL was then dialyzed into PBS 
and diluted to a final concentration of 80.4 μg/ml prior to use in this assay. DHR was 
prepared as a 50 mM stock solution in anhydrous DMSO. 5 μl apoB depleted serum was 
combined with oxidized LDL protein at a final concentration of 1.4 μg/ml and brought up to 
a volume of 173 μl with phosphate buffered saline (PBS). DHR was diluted with PBS to a 
500 μM concentration and 2 μl was added to each well for a final DHR concentration of 5.95 
μM. All samples were assayed in triplicate. Fluorescence of each well was measured for 1 h 
at 37 °C using a BioTek Synergy HT plate reader at absorption 485nm and emission 528 nm. 
HDL anti-oxidative capacity was calculated as the endpoint fluorescence of DHR incubated 
with apoB depleted serum minus the optical density of DHR alone. Data was normalized to 
the LDL blank on the plate. Supplement Figure 2 shows reproducibility. Interassay CV is 
3.5%
HDL Subspecies
370 μl of frozen serum (−80°C) was applied to three Superdex 200 Increase columns 
(10/300, GE Healthcare) arranged in series (22). To relate gel filtration fractions to 
traditional density-centric lipoprotein definitions (LDL, VLDL and HDL) we use the 
presence of apoB, the core constituent of LDL, as the key distinguisher. Therefore, the 
VLDL/LDL range is defined as fractions 15−19 due to the presence of apoB. Fractions 20–
29 are considered HDL because their diameters are consistent with measurements for 
density-isolated HDL and because of their abundance of the major HDL protein, apoA-I 
(details have been previously published (22) and see Supplement Figure 3). Choline-
containing phospholipid and total cholesterol were measured in each fraction with kits from 
Wako (Richmond, VA) and Pointe Scientific (Canton, MI), respectively. Supplement Figure 
4 shows the subspecies profile is not altered by freezing.
Cholesterol efflux in HDL Subspecies
Cholesterol efflux was also measured in the aforementioned HDL-associated gel filtration 
fractions. Given we have previously shown that the majority of cholesterol efflux occurs 
between fractions 20–25 (23), only these fractions were evaluated. Efflux across HDL 
fractions and subsequent mass spectrometry (MS) analysis was performed on a subset of 
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n=6 individuals due to unavailable sample on n=4. Characteristics of the participants studied 
were no different from the entire group. As above, efflux was assessed as net movement 
of 3H cholesterol from J774 macrophage cells. Instead of apoB depleted serum, we used 
26.7% v/v of each serum fraction in freshly made in basal media (consisting of DMEM 
containing 0.2% BSA) with 2 μg/ml ACAT inhibitor and 0.3 mM 8-Br-cAMP. It should be 
noted that each serum fraction is approximately 50-fold diluted compared with serum. HDL 
lipid peroxidation and HDL inflammatory index assays were attempted on HDL subspecies 
but data were not dose dependent nor reproducible. Supplement Figure 5 demonstrates that 
the increase in cholesterol efflux capacity represents an increase in the number of particles 
contained in that fraction.
HDL Proteomics
We applied shotgun proteomics to determine if there were changes in the HDL proteome 
following VSG (17). HDL fractions were prepared as previously described (22). Further 
details on sample preparation and mass spectrometry data analysis are provided in the 
supplement. Raw spectral counts are presented and no data normalization was performed. 
Correction for multiple comparisons for the proteomic data was not performed given the 
exploratory nature of this work.
Results
Clinical Characteristics
Characteristics of the participant’s pre-surgery and 1 year post VSG are presented in Table 1. 
At the baseline visit prior to surgery, participants were a mean age of 17.4 ± 1.6 years (age 
range 15.5–19.8 years). 90% of the participants were Caucasian and all were male. All 
participants were severely obese defined as body mass index ≥35 or a BMI ≥120% of the 
95th percentile for age and sex. None were on lipid lowering medication or metformin. One 
participant reported taking an ACE inhibitor for hypertension.
Follow-up data were obtained at a mean age of 18.4 ±1.5 years, approximately 1 year after 
VSG. At follow-up, the mean BMI decreased by 32%, p<0.01, Figure 1. Total cholesterol 
and LDL-C minimally changed at 1 year post-surgery, while HDL-C increased by 23% 
percent and triglycerides decreased by 25%. Fasting insulin, glucose, and HOMA-IR were 
significantly lower at follow-up (p<0.05). Systolic blood pressure was also lower (p<0.05). 
None of the participants were on lipid or blood pressure lowering medication or metformin 1 
year post VSG.
HDL Function
We tested HDL function both pre and post-surgery using three independent assays. The 
function most commonly associated with HDL is the ability to move (efflux) cholesterol 
from the plasma membrane of macrophages. Using J774 mouse macrophages (ATCC, 
Manassas, VA) stimulated with cyclic AMP, we measured the capacity of plasma samples to 
accept radiolabeled cholesterol. Since apoB containing lipoproteins (VLDL and LDL) are 
depleted in these samples, the primary lipoprotein acceptor is HDL. Figure 2a shows that 
overall cholesterol efflux capacity improved post VSG. Mean cholesterol efflux capacity 
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was 12% higher in participants post VSG (baseline mean ± SE 0.94 ± 0.05 vs. post VSG 
1.04 ± 0.06, p=0.0056). We next measured HDL lipid peroxidation. Figure 2b shows mean 
HDL lipid peroxidation decreased by 30% post VSG (baseline mean ± SE 16.4 ± 1.1 vs. 
11.4 ± 0.9, p=0.0047). Finally, we measured the ability of HDL in apoB depleted plasma to 
mitigate oxidation of LDL. Figure 2c shows that mean HDL anti-oxidative capacity 
improved by 25% post VSG (baseline mean ± SE 4.8 ± 0.3 vs. 3.6 ± 0.3, p=0.0029).
Lipoprotein Subspecies
To determine effects of VSG on HDL subspecies, we isolated subspecies by size using gel 
filtration chromatography. Plasma from n=14 lean adolescent males (dotted line in Figure 3), 
mean age 16.3 ± 2.7 years, show three distinct peaks when analyzed for phospholipid. 
Fractions 15–19 contains VLDL/LDL sized particles while fractions 20–30 encompasses 
HDL sized particles with fractions 27–30 representing relatively small, lipid-poor HDL 
species. Prior to surgery, adolescents with severe obesity (in black) exhibited a strikingly 
reduced level of large HDL sized particles (reduced phospholipid and cholesterol 
concentrations in fractions 20–23, p<0.05) compared to lean adolescents and an increase in 
small HDL sized particles (higher phospholipid content in fractions 25–26, p<0.05), 
consistent with our previous findings in youth with obesity and type 2 diabetes (17).
After VSG, there was a remarkable rescue of the large HDL subspecies (phospholipid 
content fraction 21, p= 0.0055 and fraction 22, p= 0.0002 and cholesterol content in 
fractions 20–23, all p<0.05) compared to baseline (Figure 3a & b). Indeed there was no 
difference between individuals who had undergone VSG and lean adolescents. Notably, 
there was also no change in VLDL/LDL fractions post VSG, a finding consistent with the 
clinical lipid measurements. To determine if these changes in large HDL particles were 
associated with a change in HDL function, we assessed cholesterol efflux capacity in equal 
volumes of these fractions. After VSG, we noted a significant improvement in cholesterol 
efflux capacity (Figure 4) in HDL fractions 21 (p=0.0211) and 22 (p=0.0170). Taken 
together, these data show that metabolic surgery in severely obese participants with VSG, 
increases the concentration of large HDL particles to levels comparable to those observed in 
lean adolescents and improved HDL function.
Proteomics
Finally, we also sought to determine if proteins associated with large HDL subspecies in 
fractions 21–22 (or the HDL proteome) change after VSG. Forty-eight HDL associated 
proteins (defined as HDL consensus proteins that have been found in 3 or more independent 
studies of HDL proteomics (16)) were identified in our samples. All proteins were detected 
both pre- and post-VSG. Twelve proteins showed higher (but not statistically different) 
peptide counts after VSG, 22 proteins were lower and 14 proteins showed no difference post 
VSG (see Table S1 in supplement for a complete list of all proteins). In fraction 21, all major 
HDL apolipoproteins including apoA-I, A-II, apoC-I, apoC-III, apoJ, PON-1 trended higher 
after VSG (Figure 5, however, only apoE was significantly higher (p<0.05). Proteins that 
were significantly lower in fraction 21 after VSG included complement factor H and plasma 
kallikrein. In fraction 22, apoA-I was significantly higher post VSG (Figure 5), while plasma 
kallikrein was lower, both p<0.05.
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Discussion
We show that one year following VSG there is substantial improvement of atherogenic HDL 
subspecies profile in youth with severe obesity that approaches lean adolescents, despite 
incomplete resolution of obesity. Importantly, we also documented there is also significant 
improvement in HDL function as measured by increased cholesterol efflux capacity, 
decreased lipid peroxidation, and improved anti-oxidative capacity. These data suggest that 
metabolic weight loss surgery either via improved weight or insulin resistance or an 
independent mechanism may be associated with improved cardiovascular health.
To date there has only been a single study conducted in adolescents evaluating HDL 
function. In that study HDL function measured by the phosphorylation of eNOS did not 
improve one year after Roux-en-Y gastric bypass. In fact, the authors postulated that HDL 
function may not improve with surgery in adolescents (24). However, our data show clear 
improvements in cholesterol efflux capacity, anti-oxidative capacity and lipid peroxidation 
after one year following VSG. The discrepant results between the former study in 
adolescents and here may be explained by the larger sample size, alternative HDL functions 
studied, differences by surgery type, or other factors. Our findings are in agreement with 
adult studies that show HDL function (apoB depleted plasma or HDL isolated by 
ultracentrifugation) measured by cholesterol efflux (25), oxidation potential (26) and 
endothelial function (27) improve following Roux-en-Y gastric bypass.
Not all participants had improved HDL function post VSG as seen in the Figure 2. In fact, 
some individuals changed very little from baseline to follow-up. However, it was not the 
same individuals that lacked improvement by all three functional assays. In addition, the 
degree of improvement did not correlate with BMI loss or HDL-C levels. Thus, 
improvements in HDL function measured by these assays are likely dedicated by 
combination of metabolic risk factors.
In addition to evaluating HDL function we show large HDL subspecies increase after 
metabolic surgery. Prior work has shown that HDL exists as a family of subpopulations that 
is highly heterogeneous in structure, composition, metabolism, function and likely 
atherogenic potential (16, 28). Furthermore, large HDL particles have traditionally been 
inversely associated with cardiovascular risk while high concentrations of small HDL 
particles are typically positively correlated with cardiovascular risk demonstrating that size 
of HDL particles is important (29–32). After Roux-en-Y gastric bypass, studies in adults 
have shown the appearance of large, lipid-rich particles (either alpha-1 particles by 2D gel 
electrophoresis (26, 33) or HDL2 isolated by ultracentrifugation (25)). We chose to study 
HDL subpopulations using gel filtration chromatography over the former methods because 
in addition to allowing the recovery of the particles for functional analysis (23), it is 
performed at physiological pH and ionic strength without high g-forces resulting in 
significantly less proteome rearrangement compared to ultracentrifugation (34). We show 
that large atheroprotective HDL particles increase after VSG. However, whether these 
particles are directly responsible for the improved HDL function observed post VSG 
remains to be determined.
Davidson et al. Page 8
Int J Obes (Lond). Author manuscript; available in PMC 2017 April 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We noted relatively few changes in the HDL proteome following VSG, similar to prior work 
(24). While these results could suggest that the HDL proteome does not change with surgery 
as postulated by Matsou et al (24), it is possible that we were underpowered to detect 
differences. Indeed, 34 proteins trended toward changes after VSG (up or down). One 
protein that did significantly change was apoE. This finding parallels our previous study that 
found obese youth with diabetes have decreased apoE compared to lean individuals (17). 
Prior work suggests that apoE associated with large HDL particles may confer vascular 
protection by competing with LDL for heparin-sulfate proteoglycans in the vessel wall, the 
process that initiates atherosclerosis (35). In fact, lower amount of large apoE HDL particles 
in patients with type 2 diabetes is thought to be one reason for their accelerated CVD (35). If 
apoE-rich large HDL competes with LDL, the benefits might not only include the 
displacement of potentially oxidizable LDL in the vessel wall but our observation of 
improved HDL anti-oxidative capacity suggest a potential double benefit. ApoE rich large 
HDL may be an important mechanism by which metabolic surgery improves cardiovascular 
health. Confirmation of this hypothesis requires further detailed studies.
Other proteins that changed post VSG include ApoA-I and plasma kallikrein. ApoA-I is 
HDL’s major structural and functional apolipoprotein and is thought to be critical for many 
of HDL’s functions including cholesterol efflux and generating large HDL particles by 
lecithin-cholesterol acyltransferase (LCAT). Therefore, it is not surprising apoA-I increased. 
Plasma kallikrein significantly decreased in both fraction 21 and 22. Plasma kallikrein is a 
serine protease thought to play a role in the pathogenesis of thrombosis, inflammation, and 
blood pressure regulation. When plasma concentrations become high, kallikrein is thought to 
perpetuate CVD (36). In fact, kallikrein inhibitors are being proposed as a novel class of 
drugs for the treatment of CVD. The fact that following VSG, HDL associated kallikrein 
decreases suggests there may be additional atheroprotective benefits post VSG. Of note, 
systolic blood pressure was lower post VSG in these adolescents.
There are some limitations. First, while HDL lipid peroxidation and HDL anti-oxidative 
capacity are both well-established assays that correlate with HDL functions they are not 
direct HDL functional assays, per say. However, each was chosen because it has been shown 
to be a reliable and reproducible surrogate measure that correlates with CVD outcomes (15, 
37, 38). Second, we focused on cAMP mediated efflux not cAMP-independent cholesterol 
efflux or net mass cholesterol flux therefore we cannot determine if these pathways are 
altered with surgery. Finally, since this was an observational study we cannot address 
underlying mechanisms. We do not know whether the observed improvements in HDL 
subspecies and function are due to weight loss, improved insulin resistance, altered gut 
physiology (27) or another mechanism. Future studies that include larger sample sizes, 
alternative surgery types (i.e. Roux-en-Y) and multiple time points are needed.
In conclusion, we show large atheroprotective HDL subspecies emerged by 1 year after VSG 
surgery to levels similar to that observed in lean adolescents. Furthermore, we show 
improved HDL atheroprotective function. At this time it is unclear whether improved 
function is a reflection of more particles or improved function of existing particles but at 
least for efflux our data shows the former is more likely. As metabolic surgery grows in 
popularity as a weight loss option in adolescents, it is e important to gain a full 
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understanding of its risks and benefits. Our data suggests that weight loss and improvement 
in the lipid profile may not be the only benefit of weight loss surgery; indeed improved HDL 
function may alter the risk of future cardiovascular events in this population, an issue of 
major public health concern (39).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Body mass index pre-surgery and post VSG. Individual data points are plotted for n=10 
participants. p value from paired t-test was 0.003.
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Figure 2. 
HDL Function pre and post VSG. Individual data points are plotted for n=10 participants. p 
value obtained via paired t-test. A) Cholesterol efflux capacity, p=0.0056. B) HDL 
oxidation, p-value =0.0047. C). HDL anti-oxidative index, p = 0.0029.
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Figure 3. 
Phospholipid and cholesterol across lipoprotein fractions. A) Phospholipid and B) 
cholesterol concentration of serum fractionated by gel filtration chromatography pre (—●—
black) and post (—▲—gray) vertical sleeve gastrectomy (VSG). Data are mean and SE for 
pre and post VSG for n=10 participants. Dotted line (–▽–) shows a lean control group 
(n=14) from a separate study for reference. * indicates significant differences pre and post 
VSG, p<0.01.
Davidson et al. Page 15
Int J Obes (Lond). Author manuscript; available in PMC 2017 April 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Cholesterol efflux capacity across HDL subspecies. Data are mean and SE for n=6 
participants. * indicates p<0.05 by paired t-test. Each sample was assayed in triplicate.
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Figure 5. 
HDL associated proteins in fractions 21 (panel a) and 22 (panel b). Data are mean and SE of 
raw spectral counts pre (black bars) and post VSG (gray bars) for n=6 participants.
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Table 1
Study participants at pre and post sleeve gastrectomy.
Variable Baseline 1 year post VSG Percent Change
Age (years) 17.4±1.6 18.4±1.5 –
Race (Caucasian) 9 (90%) – –
Height (cm) 126±86 126±86 0%
Weight (kg)* 167 ±36 111± 25 ↓32%
Body Mass Index (kg/m2)* 52.1± 9.8 35.3± 9.0 ↓32%
Total cholesterol (mg/dL) 167± 56 157± 29 ↓1.4%
LDL cholesterol (mg/dL) 102 ±41 96± 27 ↓1.4%
HDL cholesterol (mg/dL) 34± 7 42±11 ↑ 23%
Triglycerides (mg/dL) 154± 99 98±49 ↓25%
Fasting insulin (mcIU/mL)* 43.1±19.1 13.0±10.0 ↓71%
Fasting glucose (mg/dL)* 98 ± 14 78±8.2 ↓19%
HOMA-IR* 10.0 ± 5.3 2.5 ± 2.0 ↓75%
Systolic Blood Pressure (mmHg)* 136±9 124±10 ↓8.7%
Diastolic Blood Pressure (mmHg) 70±11 69±10 ↓0.8%
VSG= vertical sleeve gastrectomy. HOMA-IR= Homeostatic Model Assessment of Insulin Resistance. Data from n=10 participants. Mean ± SD or 
number (percent).
*indicates p <0.05 between baseline and post VSG tested by paired t-test.
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